Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00144677 · ClinicalTrials.gov registry record · Phase 2
Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation
A Phase 2 study of Myelodysplastic Syndromes and Acute Lymphoblastic Leukemia, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT00144677 is a Phase 2 study of Myelodysplastic Syndromes and Acute Lymphoblastic Leukemia that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 30 participants, below the 285-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00144677, a Phase 2 study of Myelodysplastic Syndromes and Acute Lymphoblastic Leukemia, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the ability of sirolimus to prevent graft versus host disease (GVHD) in patients following stem cell transplant from an unrelated donor. This trial is designed to test the hypothesis that elimination of methotrexate in the unrelated donor group would lead to less transplant-related toxicity while still preserving the effective control of GVHD.
Conditions Studied
Interventions
- DRUG tacrolimus
- DRUG sirolimus
Study Locations (1)
Massachusetts
- Dana-Farber Cancer Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2003-11 |
| Est. Completion | 2006-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00144677
The ClinicalTrials.gov registry entry for NCT00144677 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 285-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (89% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Myelodysplastic Syndromes appearing as the primary indexed condition, and to 2 interventions - of which tacrolimus is the first listed.
NCT00144677 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00144677 about?
NCT00144677 is a clinical study titled "Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation". The purpose of this study is to evaluate the ability of sirolimus to prevent graft versus host disease (GVHD) in patients following stem cell transplant from an unrelated donor. This trial is designed to test the hypothesis that elimination of methotrexate in the unrelated donor group would lead to ...
What is the current status of trial NCT00144677?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2003-11. Estimated completion is 2006-06.
What conditions does trial NCT00144677 study?
This clinical trial studies the following conditions: Myelodysplastic Syndromes, Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma, Graft-Versus-Host Disease, Acute Myelogenous Leukemia.
What interventions are being tested in trial NCT00144677?
The interventions under investigation include: tacrolimus (DRUG), sirolimus (DRUG).
Who is sponsoring clinical trial NCT00144677?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00144677 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelodysplastic Syndromes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)
RECRUITING · Phase 2
-
Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations
RECRUITING · Phase 2
-
Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms
RECRUITING · Phase 2
-
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RECRUITING · Phase 2
-
Ascorbate in Myelodysplastic Syndrome
RECRUITING · Phase 2
-
A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome
RECRUITING · Phase 2
Explore more on PlainTrial
Myelodysplastic Syndromes
All registered trials for this condition
Acute Lymphoblastic Leukemia
All registered trials for this condition
Massachusetts
All trials with a study site in Massachusetts
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.